Skip to main navigation

Investor Relations

Home
Investors & Media
Contact Us
Careers

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Press Releases

Year

Jun 01, 2023

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences

May 25, 2023

BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia

May 16, 2023

BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) Program

May 08, 2023

BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights

May 02, 2023

BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference

Apr 24, 2023

BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023

Mar 14, 2023

OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

Mar 09, 2023

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

Feb 23, 2023

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

Feb 21, 2023

BioXcel Therapeutics to Ring Nasdaq Stock Market Closing Bell Today

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Site - Investor Tools

Print Page

Tear Sheet

Email Alerts

RSS Feeds

Contacts

Search

About Us
Our Products
Our Pipeline
Our Science
Patients & Advocacy

Home
Investors & Media
Contact Us
Careers

Copyright © 2023 BioXcel Therapeutics, Inc. All Rights Reserved.

Privacy Policy
Disclaimer
Sitemap